sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
ugagaacauacuuuccccuuaaa | 621 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ugagaacauacuuuccccuuaaa | 311 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uguccagcuuuauugggaggcca | 592 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uguccagcuuuauugggaggcca | 230 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ucccaauaaagcuggacaaga | 130 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ucccaauaaagcuggacaaga | 440 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ucccaauaaagcuggacaaga | 708 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ucccaauaaagcuggacaaga | 716 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gccuccaagacgguccaggau | 455 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gccuccaagacgguccaggau | 456 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gccuccaagacgguccaggau | 249 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gccuccaagacgguccaggau | 248 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
auuagggacagcauguuuaggug | 645 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
auuagggacagcauguuuaggug | 335 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 187 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 555 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 562 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 194 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 683 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 198 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 193 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 192 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 207 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 219 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 584 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 582 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 560 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 197 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 196 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 563 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 195 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 570 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 661 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 553 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 216 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 583 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 545 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 17 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 184 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 213 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 211 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 575 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 546 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 183 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 201 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 558 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 189 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 549 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 548 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 190 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 200 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 14 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 573 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 556 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 208 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 186 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 547 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 581 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 578 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 551 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 552 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 557 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 700 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 554 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 569 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 188 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 185 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 222 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 212 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 559 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 221 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 220 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 550 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agaauacugucccuuuuaagcaa | 191 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agcuggauaagaagcugcugu | 271 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agcuggauaagaagcugcugu | 478 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ccugagaccucaauaccccaa | 365 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ccugagaccucaauaccccaa | 55 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ccugagaccucaauaccccaa | 366 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ccugagaccucaauaccccaa | 56 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ugggguauugaggucucaggcag | 156 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ugggguauugaggucucaggcag | 517 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ugggguauugaggucucaggcag | 155 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ugggguauugaggucucaggcag | 518 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcacugagaauacugucccuuuu | 590 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcacugagaauacugucccuuuu | 228 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
auguuuaggugagaucuagggag | 626 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
auguuuaggugagaucuagggag | 316 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gucccuaauaaagcuggauaa | 276 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gucccuaauaaagcuggauaa | 483 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcuuaaaagggacagucuucu | 92 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggcugccugagaccucaauac | 364 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggcugccugagaccucaauac | 54 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ugcauccuuggcggucuuggugg | 495 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ugcauccuuggcggucuuggugg | 496 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ugcauccuuggcggucuuggugg | 134 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ugcauccuuggcggucuuggugg | 133 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acuugggguauugaggucucagg | 164 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acuugggguauugaggucucagg | 526 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gaaaggcuacuggagcaaguu | 256 | US11408001B1 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | 20,220,809 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.